Global Clinical Next-generation Sequencing Market 2022 - Snapshot

The global clinical next-generation sequencing market is anticipated to increase by USD 18 billion till 2028 at an average annual growth of 23.4 percent as per the latest report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the component, disease class, disease category, test complexity, test purpose, and region. The global market data on clinical next-generation sequencing can be segmented By component instrument, workflow solution (kits, services, etc.). Clinical next-generation sequencing market is further segmented by disease class: cancer, non-cancer. The non-cancer segment captured the largest share of the market in 2021. Based on disease category, the clinical next-generation sequencing market is segmented into: cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic immune, neurological, oncology, reproductive health, transplantation. According to the research, the oncology segment had the largest share in the global clinical next-generation sequencing market. On the basis of test complexity, the clinical next-generation sequencing market also can be divided into: hotspot, multi-gene, single gene, whole genome, whole/targeted exome. The multi-gene segment held the largest revenue share in 2021. Clinical next-generation sequencing market by test purpose is categorized into: diagnosis, monitoring, screening/early detection, therapy guidance. The clinical next-generation sequencing market by region can be segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

The global clinical next-generation sequencing market is highly competitive. The key players in the clinical next-generation sequencing market include ANGLE plc, Becton Dickinson and Company, BGI Group, BioceptInc., BiodesixInc., Biolidics Limited, Bio-Techne Corporation, Burning Rock Biotech Limited, CareDxInc., Danaher Corp., Epigenomics AG, Eurofins ScientificSE, EXACT Sciences Corporation, Fulgent Genetics Inc., GeneDx Inc., Guardant HealthInc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Qiagen N.V., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
- Get a detailed picture of the Global Clinical Next-generation Sequencing Market
- Identify segments/areas to invest in over the forecast period in the Global Clinical Next-generation Sequencing Market
- Understand the competitive environment, the markets leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Clinical next-generation sequencing market overview
Part 4. Market breakdown by component
Instrument
Workflow solution (kits, services, etc.)
Part 5. Market breakdown by disease class
Cancer
Non-cancer
Part 6. Market breakdown by disease category
Cardiovascular
Clinical microbiology and infectious diseases
Mendelian disorders
Metabolic/immune
Neurological
Oncology
Reproductive health
Transplantation
Part 7. Market breakdown by test complexity
Hotspot
Multi-gene
Single gene
Whole genome
Whole/targeted exome
Part 8. Market breakdown by test purpose
Diagnosis
Monitoring
Screening/early detection
Therapy guidance
Part 9. Market breakdown by region
Asia Pacific
Europe
North America
Rest of the World (RoW)
Part 10. Key companies
ANGLE plc
Becton, Dickinson and Company
BGI Group
Biocept,Inc.
Biodesix,Inc.
Biolidics Limited
Bio-Techne Corporation
Burning Rock Biotech Limited
CareDx,Inc.
Danaher Corp.
Epigenomics AG
Eurofins ScientificSE
EXACT Sciences Corporation
Fulgent Genetics Inc.
GeneDx Inc.
Guardant Health,Inc.
Illumina, Inc.
Koninklijke Philips N.V.
Merck KGaA
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
Qiagen N.V.
Quest Diagnostics Incorporated
Roche Holding AG
Thermo Fisher Scientific Inc.
Part 11. Methodology

Global Whole Exome Sequencing Market 2023

DescriptionThe Whole Exome Sequencing Market is poised for substantial growth, with a projected increase from USD 1.43 billion in 2022 to USD 3.75 billion by 2029. This growth is expected

USD 1950 View Report

Global Continuous Bioprocessing Market 2023

DescriptionThe global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 million in 2022 to USD 443.1 million by 2029, registering a compound annual growth rate (CAGR) of

USD 1950 View Report

2024 Global Clinical Chemistry Immunodiagnostics Market

2024 Global Clinical Chemistry and Immunodiagnostics Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for 100 Tests, Emerging Technologies and Trends, Instrumentation Pipeline, Growth OpportunitiesThe new

USD 18500 View Report

Global Clinical Chemistry Immunodiagnostics Market Supplier Shares

2024 Global Clinical Chemistry and Immunodiagnostics Market in the US, Europe, Japan--2023 Supplier Shares and Strategies by Country, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drug, Cancer, Chemistry,

USD 14500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available